1. 1) 日本泌尿器科学会編: 膀胱癌診療ガイドライン2019年版, p 66-83, 医学図書出版, 東京, 2019.
2. 2) Flaig TW, Spiess PE, Agarwal N, Bangs R, Boojian SA, Buyyounouski MK, Chang S, Doens TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack EA, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Teard J and Eright JL: NCCN Clinical Practice Guidelines in Oncology Version 3. 2020, 2020.
3. 3) Witjes JA, Brunis M, Cathomas R, Comperat E, Cowan NC, Gakis G, Hernandez V, Lorch A, Ribal MJ, Thalmann GN, Heijden AG and Veskimae E: EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer, 2019.
4. 4) Kretschmer A, Grimm T, Buchner A, Jokisch F, Ziegelmuller B, Casuscelli J, Schulz G, Stief C and Karl A: Midterm Health-related Quality of Life After Radical Cystectomy: A Propensity Score-matched Analysis. Eur. Urol. Focus, 686, 1-7, 2019.
5. 5) U.S. Department of Health and Human Services Food and Drug Administration, Guidance for Industry, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009.